NEW YORK, July 19, 2011—Kantar Health, a leading healthcare-focused global consultancy and marketing insights company, has appointed Richard W. Martin to the position of CEO, Kantar Health Oncology. He was most recently CEO, Global Practices, at Kantar Health. In his new role, Mr. Martin will lead the continued development of Kantar Health’s global oncology business.
“Kantar Health has the largest portfolio of oncology data and insight offers in the industry resulting from early recognition by teams that Richard led of the need for comprehensive information in this area” says Lynnette Cooke, CEO of Kantar Health. “His experience and understanding of client needs and Kantar Health’s global competencies will ensure that we continue to advance our service of providing relevant and actionable advice in new product planning, market access and marketing effectiveness in oncology.”
Kantar Health’s multidisciplinary oncology team members are located in Europe, North America and Asia. Supported by their scientific, clinical, research and business competencies, the team provides their clients with business decision support on a custom engagement basis and makes available multiclient databases and resources including Oncology Market Access U.S., Oncology Market Access EU, OMT, CancerNFluence and CancerMPact.
“Kantar Health’s oncology team members are recognized as second to none in their knowledge of this complex disease area, markets and the myriad issues that impact our clients’ efforts to improve treatment,” Mr. Martin says. “It’s our mission to collectively marshal the power of our talent, offers and insights globally to help our clients accelerate progress against this terrible disease.”
Mr. Martin has over 30 years of experience in the healthcare industry. He has directly served clients in a wide variety of strategic consulting engagements in the pharmaceutical and biotech industry, including serving as President and COO of MattsonJack, a Kantar Health legacy company.